"Natalizumab" . . "3" . "Natalizumab"@en . "CZ - \u010Cesk\u00E1 republika" . "Sou\u010Dasn\u00E1 l\u00E9\u010Dba roztrou\u0161en\u00E9 skler\u00F3zy mozkom\u00ED\u0161n\u00ED (RS) nen\u00ED kauz\u00E1ln\u00ED a principi\u00E1ln\u011B ovliv\u0148uje pouze jej\u00ED imunopatogenetick\u00E9 mechanismy a ve sv\u00E9m d\u016Fsledku pouze redukuje a zpomaluje proces demyelinizace a ztr\u00E1ty axon\u016F centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu (CNS). Tato skute\u010Dnost vede k neust\u00E1l\u00E9mu hled\u00E1n\u00ED nov\u00E9 imunoterapie, kter\u00E1 bude schopna m\u011Bnit rovnov\u00E1hu imunitn\u00EDho syst\u00E9mu a bude pou\u017Eiteln\u00E1 k ovlivn\u011Bn\u00ED mechanism\u016F autoimunity. Nov\u00E9 nad\u011Bje v tomto sm\u011Bru p\u0159in\u00E1\u0161\u00ED v\u00FDzkum monoklon\u00E1ln\u00EDch protil\u00E1tek." . . . . "1"^^ . "Natalizumab"@cs . "RIV/00216208:11150/07:00004069!RIV08-MSM-11150___" . "Sou\u010Dasn\u00E1 l\u00E9\u010Dba roztrou\u0161en\u00E9 skler\u00F3zy mozkom\u00ED\u0161n\u00ED (RS) nen\u00ED kauz\u00E1ln\u00ED a principi\u00E1ln\u011B ovliv\u0148uje pouze jej\u00ED imunopatogenetick\u00E9 mechanismy a ve sv\u00E9m d\u016Fsledku pouze redukuje a zpomaluje proces demyelinizace a ztr\u00E1ty axon\u016F centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu (CNS). Tato skute\u010Dnost vede k neust\u00E1l\u00E9mu hled\u00E1n\u00ED nov\u00E9 imunoterapie, kter\u00E1 bude schopna m\u011Bnit rovnov\u00E1hu imunitn\u00EDho syst\u00E9mu a bude pou\u017Eiteln\u00E1 k ovlivn\u011Bn\u00ED mechanism\u016F autoimunity. Nov\u00E9 nad\u011Bje v tomto sm\u011Bru p\u0159in\u00E1\u0161\u00ED v\u00FDzkum monoklon\u00E1ln\u00EDch protil\u00E1tek."@cs . "Natalizumab"@en . "S" . "11150" . "RIV/00216208:11150/07:00004069" . "7"^^ . "1"^^ . "Natalizumab"@cs . . "436290" . "571;577" . "Farmakoterapie" . . . . . "1801-1209" . . . "Natalizumab"@en . "[0978228B5772]" . "Contemporary treatment of multiple cerebrospinal sclerosis is not causal and influences mainly only its immunopathogenetic mechanisms and as a result, it only reduces and slows down the demyelization process and loss of axons of the central nervous system (CNS). This has lead to an unceasing search for a new immunotherapy that might change the balance of the immune system and be applicable to affect the autoimmune mechanisms. Research of monoclonal antibodies may be promising in this direction."@en . "Tal\u00E1b, Radom\u00EDr" . "Natalizumab" . . "6" .